9th Gene Therapy Development Summit
2026-03-24 - 2026-03-26 | Revere Hotel Boston Common, 200 Stuart Street, Boston, 02116, United States
Gene therapy is entering a defining new chapter. After a period of challenge and recalibration, the field is regaining momentum, driven by resilient teams who remain committed to transforming patients’ lives. With renewed confidence, fresh investment, and major acquisitions signalling a return to growth, the industry is refocusing on overcoming the critical barriers of safety, efficacy, scalability, and commercial viability.
The 9th Gene Therapy Development Summit returns to Boston as the premier meeting point for the global gene therapy community. Bringing together 70+ senior leaders, academic and technical experts from organisations including Bayer, Astellas Pharmaceuticals, REGENXBIO, AskBio, Ocugen, CureDuchenne Ventures and more, this industry-led forum provides an unrivalled opportunity to share insights, restore confidence, and chart a sustainable path forward for gene therapy development.
Designed to span the full end-to-end development pipeline, the summit connects professionals across pre-clinical development, manufacturing, analytical development, clinical operations, and regulatory affairs. Across 3 days of cutting-edge strategic and technical sessions, attendees will gain practical learnings on next-generation delivery technologies, gene editing, assay development, and scalable manufacturing strategies, all with a focus on optimising clinical impact and improving risk–benefit profiles.
Networking sits at the heart of the summit experience. With 10+ dedicated networking breaks, a CEO & Investor Panel, and carefully curated opportunities to meet peers, partners, and decision-makers, the event is built to foster meaningful, long-term industry connections. Whether you are looking to exchange technical insights, explore collaboration opportunities, or build strategic partnerships, this is the place to connect with the people shaping the future of gene therapy.
Featuring 70+ world-leading speakers, including C-level executives, scientific innovators, and regulatory leaders, the summit offers a truly comprehensive and collaborative environment for learning, discussion, and deal-making. From early-stage development through to clinical and commercial success, this is your definitive forum to stay ahead in an evolving gene therapy landscape.
To learn more about the event, visit our website here: https://ter.li/b0hfxq

5th LNP Formulation & Process Development Summit
2026-04-06 - 2026-04-08 | The Westin Boston Seaport District, 425 Summer Street, Boston, MA, 02210, United States
Returning to Boston in April 2026, the 5th LNP Formulation & Process Development Summit is the only industry-led meeting covering end-to-end LNP development. This Summit will be providing the latest scientific content to advance your LNP development for a variety of payloads and therapeutic applications, from mRNA vaccines to next-generation cell and gene therapies.
The 2026 program will dive into 3 parallel tracks, including: Analytical Development & Characterization, Formulation & Delivery and Process Development & Manufacturing. This is your opportunity to divide and conquer, where you can send different members across your team amongst 250+ LNP innovators, to ensure you gain a comprehensive understanding of the entire LNP development pipeline. From early formulation through to commercial-scale production, you can return to your company equipped with the insights needed to accelerate your LNP-mediated medicines.
Learn more in the official event guide here: https://ter.li/y6ipkw
Curated in collaboration with our Scientific Advisory Board, Annette Bak (AstraZeneca), Luis Brito (Beam Therapeutics), and Ching Kim Tye (Sanofi), this premier forum is designed to deliver LNP-specific networking and knowledge sharing. Our unmissable agenda highlights include:

Attracting Investment & Acquisition Opportunities with Capstan Therapeutics, GV and Chiesi Global Rare Diseases
Achieving Extrahepatic Targeting with LNPs with Alnylam, Servier and Novartis
LNPs for Cell & Gene Therapy Delivery with Yoltech Therapeutics, Innorna and Corner Therapeutics
Interactive LNP-Focused Workshop Day with Novo Nordisk, GSK and Editas Medicines
Gain a Refresher on LNP Core Principles with Land Therapeutics, Beam Therapeutics and Arbor Biotechnology
Formulating Thermostable LNPs with Eli Lilly & Co and AstraZeneca

Keen to find out more? Access our event overview on the LNP website here: https://ter.li/y6ipkw

3rd Annual GLP-1 Based Therapeutics Summit
2026-04-14 - 2026-04-16 | Hotel Commonwealth, 500 Commonwealth Avenue, Boston, MA, 02215, United States
Welcome to the 3rd GLP-1 Based Therapeutics Summit – the essential industry forum dedicated to solving the critical challenges of GLP-1 combinations, mastering tolerability, drug delivery, and seizing the multi-billion dollar opportunity in non-obesity indications.
Driven by unprecedented clinical success, this revolutionary drug class has created multi-billion dollar franchises, but the market is now reaching a critical juncture where differentiation is everything. The pressure is on to move beyond monotherapy and unlock new levels of efficacy in areas like neuroscience and cardiorenal protection, promising unparalleled potential to conquer widespread chronic diseases.
The 3rd GLP-1 Based Therapeutics Summit stands as the global forum for experts dedicated to accelerating this vital progress. This year, we’re diving deep into the game-changing potential of multi-agonist combinations, next-generation tolerability, and strategic commercial planning.
Hear from the titans of the pharmaceutical industry, including Eli Lilly, AstraZeneca, Merck, and Takeda, as well as innovative biotechs and financial institutions who will share their groundbreaking research and strategies for developing best-in-class treatments that transform patient lives.
View the full event guide: https://ter.li/p453jn

SmartLab Exchange USA
2026-04-20 - 2026-04-21 | The Logan Philadelphia, One Logan Square, Philadelphia, PA, 19103, United States
The SmartLab Exchange USA is an exclusive, invitation-only event designed for senior laboratory, R&D, and digital transformation leaders across pharma, biotech, chemicals, FMCG, and food & beverage. This two-day forum brings together more than 60 decision-makers to tackle one of the industry’s most pressing challenges: how to make lab digitalization work in practice.
Every lab is on a different point in its digital journey – whether upgrading legacy systems, implementing robotics, or leveraging generative AI to streamline workflows. But the obstacles are universal: harmonizing data, scaling automation, and driving adoption across teams. The SmartLab Exchange USA focuses on practical strategies to overcome these hurdles and accelerate transformation.
What to Expect:

Interactive Roundtables: Collaborate with peers to solve common challenges.
One-to-One Meetings: Connect with curated solution providers offering tailored answers to your priorities.
Case Studies & Keynotes: Learn from industry leaders who have successfully implemented digitalization and automation.

Unlike traditional conferences, the SmartLab Exchange USA offers a highly personalized experience – no crowded exhibition halls, just focused discussions and strategic networking. This is your opportunity to benchmark your approach, discover innovative solutions, and build partnerships that will shape the future of your lab.
Who Should Attend:
Senior professionals in R&D, QA/QC, IT, and digital transformation roles who are responsible for driving innovation and operational excellence.
Spaces are strictly limited. Secure your invitation today and join us in Philadelphia for two days of strategic collaboration and innovation.

PFS & Injectable Drug Devices East Coast
2026-04-27 - 2026-04-29 | Sheraton Boston Hotel, 39 Dalton Street, Boston, MA, 02199, United States
As part of SAE’s leading PFS Series, the 2026 conference will once again bring together top experts, industry leaders, and innovators for a three-days of key insights and networking. The conference will feature a comprehensive pre-conference focus day dedicated to advancements in device design, followed by a dynamic two-day main conference featuring keynote plenaries, interactive panel discussions, and specialized topic streams covering the most pressing industry challenges and breakthrough solutions.
For more information, click here.

5th ADC Analytical Development Summit
2026-04-28 - 2026-04-30 | Hotel Commonwealth, 500 Commonwealth Avenue, Boston, MA, 02215, United States
The 5th ADC Analytical Development Summit is the industry’s only dedicated technical forum focused exclusively on solving the analytical challenges unique to antibody–drug conjugate (ADC) development. Designed for analytical, bioanalytical, and CMC leaders, the summit brings together senior experts from across pharma and biotech to advance analytical rigor, deepen product understanding, and enable regulatory-ready ADC submissions as modalities grow increasingly complex.
Why Attend

Across three content-packed days, attendees will gain practical insights to:
Optimize physicochemical, potency, and impurity analytical methods
Decode ADC heterogeneity and move beyond average DAR measurements
Develop biologically relevant bioassays for next-generation ADCs
Navigate evolving regulatory expectations and strengthen CMC strategies
Streamline analytical method transfer to QC and CDMOs

With actionable case studies and real-world lessons, you’ll stay ahead as bispecifics, dual payloads, and novel conjugate formats progress through development pipelines.
Program Highlights

22+ expert speakers from leading biopharma and biotech companies
3 in-depth workshops on advanced ADC analytical strategies
4+ panel discussions addressing current technical challenges
12+ hours of structured networking with 80+ senior analytical scientists

Featured Speakers Include
Francis Poulin (Takeda), Melvin Flores (Sutro Biopharma), John Valliere-Douglas (Pfizer), Adrienne Wildt (AbbVie), Susan Clardy (Pyxis Oncology), and Stacey Cummins-Bitz (Eli Lilly), alongside experts from AstraZeneca, Merck, BMS, Johnson & Johnson, and more.
Download the full Event Guide to explore the complete agenda, workshops, and speaker faculty: https://ter.li/opm2ur

3rd Peptide-Based Therapeutics Summit 2026
2026-04-28 - 2026-04-30 | Hilton Boston Logan Airport, One Hotel Dr, Boston, MA, 02128, United States
Peptide therapies are rapidly becoming a disruptive modality, led by Merck’s oral PCSK9 inhibitor and Johnson & Johnson’s IL23R, with the hope to develop best-in-class drugs with improved chemistry, formulation and clinical efficacy.
To shine a light on the progress of this field, the highly anticipated 3rd Peptide-Based Therapeutics Summit returns to Boston as the industry’s only dedicated platform to turbocharge the next generation of peptide discoveries through development and towards life-saving treatments.
Gathering industry leaders including Parabilis Medicines, Circle Pharma, Abbvie, Merck, Chugai Pharmaceuticals and many more, this is your premium forum to explore:

Novel computational tools
Optimize analytical assays
Formulating cell-specific delivery methods
DMPK translatability towards clinical success of peptide therapies

With the likes of Alnylam, Pfizer, MIT, Rapafusyn Pharma, a stealth start-up and more already booked on to join, be part of 100+ stakeholders from CEOs to Scientists in disciplines ranging from peptide drug discovery R&D, medicinal chemistry, pharmacology and formulation to accelerate this goldilocks modality from concept to commercialization.
For more information, click here.

2nd Neuroscience Innovation Partnering & Licensing Summit
2026-04-28 - 2026-04-29 | Revere Hotel Boston Common, 200 Stuart Street, Boston, 02116, United States
Returning for its second year and building on the momentum of an inaugural edition that drew 100+ senior attendees, the 2nd Neuroscience Innovation Partnering & Licensing Summit is engineered to facilitate multiple high-impact, in-person meetings without the distractions of a broader, less-focused setting. Deliberately timed as an exclusive touchpoint for neuroscience business leaders to reconnect between JPM and BIO through a dedicated one-to-one partnering system, bespoke matchmaking, and 100% alignment in research interests. Those attending will receive a significant competitive advantage by hearing insights on aligning data packages with expectations and by nurturing relationships with key contacts in a more exclusive setting.
Who Attends This Differentiated Business Development Initiative?
Global Pharma: Heads of Business Development, Search & Evaluation, and Asset Scouting for Neuroscience – comparing pipelines and enabling technologies to fuel future innovation.
Innovative Biotech: C-level executives and BD leaders across neurodegeneration, psychiatry, neuro-oncology, and pain – seeking feedback, validation, and strategic partnerships with pharma and investors.
Investors & Venture Capital: Leaders focused on neuroscience investments with a higher risk appetite – looking for insights into pharma strategy and access to breakthrough opportunities.
With Novartis, Roche, Biogen, and AbbVie all signing deals in the last 6 months alone, now is the time to understand how to align with pharma’s interests, to capitalize on activity and appetite for best or first-in-class neuroscience assets.
Learn more: https://ter.li/o2406m

5th GPCRs-Targeted Drug Discovery Summit
2026-04-28 - 2026-04-30 | The Colonnade Hotel, 120 Huntington Ave, Boston, MA, 02116, United States
The GPCR field is experiencing a renaissance, driven by renewed investment, clinical progress, and next-generation technologies unlocking hundreds of previously untargeted receptors. Furthermore, we’ve recently seen Takeda and Iambic Therapeutics’ $1.7bn partnership to advance AI-driven small molecule programs, and Kainova Therapeutics securing $32m CAD to accelerate immuno-oncology and inflammation therapies, momentum in the GPCR space continues to build. The race is on to validate new GPCRs, understand dynamic activation mechanisms, and develop assays that better predict therapeutic efficacy and guide smarter candidate selection.
Returning as the only industry-led meeting dedicated to GPCR drug discovery, the 5th GPCR-Targeted Drug Discovery Summit features a jam-packed agenda with:

12+ companies unveiling never seen before data
12+ C-Level speakers
9+ presentations on non-small molecule GPCR-targeting drug discovery

This is the place to learn about the latest targets, tools, and therapeutic strategies. Join 80+ GPCR-focused leaders across biopharma to share insights, build collaborations, and accelerate next-generation therapeutics from discovery to clinic.
To know more visit: https://ter.li/etb3m3

3rd Measuring Patient Engagement Summit
2026-05-05 - 2026-05-07 | The Colonnade Hotel, 120 Huntington Ave, Boston, MA, 02116, United States
Patient engagement has shifted from a “nice to have” to a strategic necessity.
With regulators expecting defensible evidence, executives demanding clear ROI, and funding under tighter scrutiny, every engagement initiative must show measurable value. Yet many organizations still struggle to demonstrate the true impact of their work.
The 3rd Measuring Patient Engagement Summit is the only event dedicated entirely to transforming patient engagement into credible, quantifiable outcomes. Over three days, more than 70 senior leaders from pharma, biotech, and patient advocacy will come together to share frameworks, tools, and real-world approaches that prove how patient insights drive results across development, access, and commercialization.
Through interactive workshops, case studies, and collaborative sessions, attendees will:

Shift from anecdotal reporting to robust, outcome-based evidence
Benchmark strategies, co-develop frameworks, and measure impact across multi-year programs
Translate engagement activities into meaningful influence for regulators, executives, and patient communities
Walk away with peer-tested methods, practical tools, and actionable insights to elevate engagement from activity to strategic value

Measuring activity isn’t enough anymore – demonstrating impact is what moves the industry forward.
This summit offers a unique non-competitive environment where you can benchmark your approaches, collaborate directly with peers, and gain practical tools to clearly demonstrate the value of patient engagement. For teams facing tighter budgets, heightened scrutiny, and rising expectations from stakeholders, it’s the essential gathering to shift from anecdotal stories to evidence-backed impact, and to elevate patient‑centric initiatives into strategic, measurable drivers of organizational success.
To know more visit: https://ter.li/8hkio4

Investigative & Preclinical Toxicology Summit 2026
2026-05-12 - 2026-05-14 | The Colonnade Hotel, 120 Huntington Ave, Boston, MA, 02116, United States
Optimize Model Selection, Accelerate Timelines, Improve Predictivity of Toxicity
Dates: May 12-14 | Location: Boston, MA
Why Attend
With nearly 90% of drug candidates failing in the clinic and one-third of those failures driven by safety preclinical toxicology has reached a critical inflection point. Traditional models are no longer sufficient to predict human risk, leading to costly late-stage attrition and stalled pipelines.
The 2026 summit marks a new era for toxicology. Following the FDA’s 2025 roadmap to reduce reliance on animal testing, adoption of New Approach Methodologies (NAMs), including in vitro, microphysiological, and computational models, is accelerating. CROs and technology developers are releasing innovative platforms, but challenges remain around predictivity, validation standards, and regulatory alignment.
What You’ll Learn
This industry-led forum is the only meeting dedicated to benchmarking what truly works in predictive toxicology. Key focus areas include:

Evaluating in vivo, in vitro, and in silico strategies
Sharing real IND case studies
Defining fit-for-purpose model selection across modalities
Advancing NAM adoption while ensuring regulatory compliance

Who Should Attend
If you are responsible for:

De-risking first-in-human decisions
Implementing innovative toxicology strategies
Improving safety translation from preclinical to clinic

…this summit is your essential forum to separate innovation from hype and build strategies that stand up both clinically and regulatorily.
📥 Download the Event Guide to explore the full agenda, speakers, and registration details:
Organiser Name: Hanson Wade
Contact: Nisha Poyser-Reid
info@hansonwade.com
(+1) 617 455 4188

7th TCR-Based Therapies Summit
2026-05-18 - 2026-05-20 | The Colonnade Hotel, 120 Huntington Ave, Boston, MA, 02116, United States
New assets have entered clinic, whilst dozens more have been disclosed, and recent investments such as, T-Therapeutics’ $91M Series A extension to advance their bispecific towards the clinic and Anocca’s SEK 440M raise, pinpoint how funding and portfolio decisions have the power to define the trajectory of the TCR field.
It is in this context that the 7th TCR-Based Therapies Summit returns to unite fellow biopharma experts in address shared challenges and to bridge the gap between promising clinical data and long-term, commercially viable TCR-based approaches.
Across three focused days, enter into open discussions, benchmark with peers, participate in practical problem-solving and hear new data in presentations led by Immunocore, Enara Bio, Regeneron, Eureka Therapeutics, T-Cypher Bio, Zelluna Immunotherapy, and Aethon Therapeutics.
Join us in empowering the community to shape a more durable, scalable, and commercially robust future for TCR-based therapies.
To know more visit: https://ter.li/uhpzx3

4th Nasal Formulation & Delivery Summit
2026-05-19 - 2026-05-21 | Hilton Boston Logan Airport, One Hotel Dr, Boston, MA, 02128, United States
Biopharma investment into the formulation, delivery, and commercialization of intranasal therapies is at an all-time high, and there has never been such an opportunistic time to pursue nasal delivery. Alongside the market projection for intranasal therapies being forecasted to reach $21.2 billion by 2032, 2025 breakthroughs included Atzumi being approved for migraine treatment, and Eli Lilly’s Baqsimi now being applied to severe Hypoglycemia. The clock is ticking for biopharma to master their formulations first time for systemic and CNS targeting, streamline preclinical and clinical trial success, and achieve regulatory approval to drive products to market.
In response to this recent momentum, the 4th Nasal Formulation & Delivery Summit is uniting 70+ biopharma professionals across C-levels, Formulation, Intranasal, and roduct Development to overcome drug and device combination challenges, perfect preclinical translation, and alter formulations, to achieve commercial viability for intranasal products. This is the only forum specifically dedicated to industry-focused intranasal formulation, targeting both systemic and CNS delivery. We will combine a hyper-relevant technical focus with a commercial angle to help see your products through concept to clinic.
In uniting large pharma, expanding mid-sized biotech, and startup innovators, you will achieve technical excellence for your formulation and delivery that will future-proof commercialization, and meet potential partners who will co-develop your intranasal therapies. Adopt groundbreaking insights on pre-clinical and clinical intranasal study data for different delivery methods to obtain practical takeaways that will transform the trajectory of your intranasal success. Join biopharma in igniting a new era of innovation where intranasal delivery holds the power to unparalleled medical benefits.
To know more visit: https://ter.li/eqlf0s

LEAP HR: Life Sciences West
2026-05-19 - 2026-05-21 | Wyndham San Diego Bayside, 1355 N Harbor Dr, San Diego, CA, 92101, United States
Returning for its 8th year, LEAP HR: Life Sciences West brings together 100+ senior HR leaders from scaling and stabilizing biotech organizations to navigate volatility and drive measurable business impact.
Across three days of high-impact sessions, including case studies, benchmarking, roundtables, and structured networking, attendees will gain practical strategies to build lean HR functions, retain top talent, and respond to immigration shifts and political change.
This is the only forum dedicated to the unique people challenges facing West Coast life sciences organizations. Join us this May to connect, benchmark, and lead with confidence in a rapidly evolving market.
To know more visit: https://ter.li/caoti5

5th ALS Drug Development Summit
2026-06-02 - 2026-06-09 | The Colonnade Hotel, 120 Huntington Ave, Boston, MA, 02116, United States
The 5th ALS Drug Development Summit returns to Boston as the ultimate platform honing industry R&D for safer, more effect and patient-relevant drugs that serve the community, driving a cure for sporadic and familial ALS.
With a brand-new agenda spanning early target exploration through to clinical design, biomarker strategy, and regulatory engagement, attendees will gain comprehensive insights into genetically validated targets, the evolving biology of TDP 43, adaptive trial design, and embedding the patient voice throughout development.
Join us for 3 days of unmissable data-driven content, with 2 tracks spanning discovery to access for the whole team:
Track A: Discovery, Preclinical & Translational – designed for CSOs, pre-clinical researchers, discovery scientists, directors of biology and research, novel modality scientists, in viva/in vitro modelling experts and many more, connect with an intimate group of discovery and preclinical experts for a more discursive session.
Track B: Clinical & Regulatory – tailor-made for medical directors, CMOs, clinical program leaders, translational and clinical development heads and clinicians and more; share expertise from diverse clinical challenges and innovation in ALS.
Designed for biotech, pharma, academia, and patient advocacy stakeholders, this unique forum will unite 100+ senior experts and 30+ speakers from companies including AbbVie, Biogen, Novartis, Eli Lilly, QurAlis, Prilenia, Sanofi, and many more.
Discover the full 2026 event guide now to explore all speakers and sessions – https://ter.li/28a6lw

5th Extrahepatic Lipid-Based Nanoparticles Delivery Summit
2026-06-02 - 2026-06-04 | Hotel AKA Boston Common, 90 Tremont Street, Boston, MA, 02108, United States
The 5th Extrahepatic Lipid-Based Nanoparticles Delivery Summit returns to Boston in June 2026 as the premier industry forum dedicated to advancing extrahepatic LNP delivery and next-generation targeted lipid nanoparticle technologies. As the field moves beyond liver-focused delivery, achieving precise, selective, tissue-specific targeting remains one of the most critical challenges in genetic medicine. With growing industry validation – including strategic acquisitions by AbbVie and Bristol Myers Squibb – confidence in targeted LNP platforms is accelerating across biopharma.
Over 3 content-rich days, 60+ experts from leading biotech, pharma, and academia will share cutting-edge data and practical insights on delivering mRNA, RNA, gene-editing, and cell therapy payloads to extrahepatic tissues, including immune cells, muscle, and adipose tissue. Attendees will explore novel targeting ligands, active and passive targeting strategies, innovative lipid chemistries, and advanced formulation approaches designed to improve biodistribution, potency, and safety profiles.
The summit will also address critical translational challenges, including targeted LNP analytics, scalability, manufacturability, and immunogenicity – key hurdles in advancing extrahepatic delivery toward clinical success. Through 13+ data-driven case studies, 6 interactive workshops, expert panel discussions, and dedicated networking sessions, participants will gain actionable strategies to accelerate development timelines and de-risk clinical progression.
With representation from pioneering organizations across the delivery ecosystem, this meeting provides a unique opportunity to benchmark progress, forge strategic partnerships, and overcome bottlenecks limiting cell-specific LNP performance. Whether optimizing formulation, engineering targeting ligands, refining preclinical models, or preparing for clinical translation, this summit delivers the technical depth required to stay at the forefront of innovation.
Visit Our Website for More Information.
https://ter.li/rt2poz

10th R&D Procurement & Sourcing in Pharma Summit
2026-06-02 - 2026-06-04 | Revere Hotel Boston Common, 200 Stuart Street, Boston, 02116, United States
The Future of R&D Procurement Excellence Starts Here!
The 10th R&D Procurement & Sourcing in Pharma Summit returns to Boston in June 2026 as the definitive meeting place for procurement, sourcing and category management leaders across pre‑clinical and clinical R&D. This flagship event is designed to support procurement teams as they transition from transactional buying to strategic, value‑driven partnership models that accelerate pipeline delivery and protect business continuity.
Bringing together senior R&D procurement leaders from global biopharma, the summit focuses on strengthening sourcing resilience, maximising CRO and CMO partnerships, embedding AI and orchestration tools, and aligning procurement strategy with scientific and operational ambition across the development lifecycle.
Visionary Faculty Includes:

Novartis – Strengthening global sourcing resilience amid geopolitical and supply‑chain disruption
Regeneron Pharmaceuticals – Optimising supplier governance and long‑term strategic partnerships
Vertex Pharmaceuticals – Integrating data, technology and AI to streamline R&D procurement operations
Takeda & UCB – Elevating procurement’s influence through early‑stage R&D decision‑making

Why Attend?

Three days of immersive learning across discovery, pre‑clinical and clinical procurement tracks
30+ expert speakers sharing real‑world case studies and practical, execution‑ready frameworks
Dedicated sessions on AI‑enabled procurement, supplier relationship management and global sourcing resilience
Extensive networking opportunities with peers shaping the future of R&D procurement and sourcing

Join us in Boston to help redefine procurement as a strategic engine for R&D innovation, delivering speed, resilience and measurable supplier value across the development pipeline.

PFS & Injectable Drug Delivery West Coast
2026-06-08 - 2026-06-10 | SAN DIEGO MARRIOTT LA JOLLA, 4240 La Jolla Village Drive, La Jolla, San Diego, CA, 92037, United States
Foster Innovation and Collaboration at the 10th Annual Pre-Filled Syringes and Injectable Drug Devices West Coast Conference!
Join us in June 2026 as SAE Media Group’s renowned West Coast event returns, bringing together biotech pioneers, pharma leaders, and device innovators to shape the future of injectable drug delivery.
This year’s conference will bring a brand NEW focus day followed by the two-day main conference offering an unparalleled platform to explore cutting-edge advances in combination product technology while fostering collaboration between pharma, device developers, and regulators.
Free to Attend for Pharma and Biotech!*
What You’ll Gain:

Actionable insights to strengthen your drug-device portfolio.
Opportunities to network with key players shaping the injectable drug delivery landscape.
A future-focused perspective on innovation, regulation, and patient-centric care.
This must-attend event is your chance to stay ahead in the rapidly evolving injectable drug delivery space. We look forward to welcoming you to the West Coast in June 2026!
Join organizations including: AbbVie, Amgen, Bristol Myers Squibb, Ionis Pharmaceuticals, Protagonist Therapeutics, Genentech and, more

*Terms and Conditions apply
To learn more and register, please click here.

5th World ADC Summit South Korea
2026-06-09 - 2026-06-11 | COEX Magok Lewest, 143 Magokjungang-ro, Gangseo-gu, Seoul, South Korea
The 5th World ADC Summit South Korea (previously World ADC Asia), taking place 9–11 June 2026 in Seoul, stands as the Asia’s premier meeting dedicated to accelerating next‑generation antibody–drug conjugate (ADC) development.
As South Korea rapidly transitions from a biosimilar‑focused market to a global innovator in precision oncology, ADCs have emerged as a centrepiece of this shift. The summit responds to this momentum by offering a comprehensive, end‑to‑end forum covering discovery, preclinical development, clinical translation, and CMC innovation. With more than 300 industry experts expected to attend, the event brings together leading organizations to exchange insights on novel and dual‑payloads, bispecific ADCs, and strategies to overcome Topo‑1 resistance and develop best‑in‑class ADCs.
Whether you are an expert or beginner in the field, join one of our three content tracks spanning early discovery through manufacturing scale‑up to get up to speed with the latest developments.
One Pass, Three Events: Part of the World Targeted Therapeutics Summit in South Korea organized by Hanson Wade, this is your opportunity to converge with peers working on targeted protein degradation (TPDs), Bispecifics, and T-cell engagers, who aim to turn South Korea into the next major global hub for biopharma innovation in targeted therapeutics.
To know more visit: https://ter.li/qznxdj

World TPD & Induced Proximity Summit South Korea
2026-06-09 - 2026-06-11 | COEX Magok Lewest, 143 Magokjungang-ro, Gangseo-gu, Seoul, South Korea
The World TPD & Induced Proximity Summit South Korea is the first and only Asian industry event dedicated exclusively to advancing targeted protein degradation (TPD) and induced proximity–based therapeutics.
As the global TPD field enters a pivotal era, with the first PROTAC approval on the horizon and multiple candidates progressing through clinical trials, South Korea has emerged as a major innovation hub, fuelled by rapid investment, strategic partnerships, and an expanding biotech ecosystem.
Designed as an end‑to‑end forum for degraders, molecular glues, and degrader antibody conjugates (DACs), the summit brings together international opinion leaders and Korean pioneers to address discovery challenges, translational strategy, clinical development, and emerging platform technologies. Deep‑dive sessions explore novel E3 ligases, AI‑enabled discovery workflows, proteomics‑driven target identification, PK/PD optimization, and case studies showcasing first‑in‑human PROTAC and DAC programs.
One Pass, Three Events: Part of the World Targeted Therapeutics Summit in South Korea organized by Hanson Wade, this is your opportunity to converge with peers working on antibody-drug conjugates (ADCs), Bispecifics, and T-cell engagers, who aim to turn South Korea into the next major global hub for biopharma innovation in targeted therapeutics.
To know more visit: https://ter.li/tslwfl

World Bispecific & T-Cell Engager Summit South Korea
2026-06-09 - 2026-06-11 | COEX Magok Lewest, 143 Magokjungang-ro, Gangseo-gu, Seoul, South Korea
The World Bispecific & T‑Cell Engager Summit South Korea is Asia’s first and only industry‑dedicated forum focused on advancing bispecific antibodies and T‑cell engagers (TCEs), modalities that are redefining the therapeutic landscape for solid tumors and immune‑driven diseases. Propelled by landmark regulatory approvals such as tarlatamab and ivonescimab, bispecifics and TCEs have captured global interest for their ability to address previously unmet medical needs.
This inaugural summit brings together international experts and regional leaders for deep‑dive sessions on advanced engineering, co-stimulation strategies, antibody masking, conditional activation, and the design of trispecific and tetraspecific formats. The agenda also explores bispecific ADCs (bsADCs), novel target selection, TCE expansion into autoimmune disease, translational biology, and early clinical readouts shaping development priorities.
As South Korea positions itself as a rising global powerhouse in targeted therapeutics, this summit provides a vital forum for advancing first‑in‑class bispecific and TCE‑based therapies with the potential to transform patient outcomes worldwide.
One Pass, Three Events: Part of the World Targeted Therapeutics Summit in South Korea organized by Hanson Wade, this is your opportunity to converge with peers working on antibody-drug conjugates (ADCs), Bispecifics, and T-cell engagers, who aim to turn South Korea into the next major global hub for biopharma innovation in targeted therapeutics.
To know more visit: https://ter.li/bw174h

8th T-Cell Engager Therapeutics Summit
2026-06-23 - 2026-06-25 | The Westin San Diego Bayview, 400 W Broadway, San Diego, CA, 92101, United States
8th T‑Cell Engager Therapeutics Summit — Your Flagship TCE Meeting
The T‑cell engager field is evolving at an unprecedented pace. With multiple clinical approvals now validating the durability and therapeutic relevance of this modality, and a new wave of next‑generation solid tumor and autoimmune programs rapidly progressing toward the clinic, TCEs have firmly established themselves as one of the most transformative forces shaping the future of immunotherapy.
Over the past year, the landscape has seen a sharp rise in investment, strategic alliances, and high‑value partnerships. Landmark collaborations, including BMS × JanuX Therapeutics, Candid Therapeutics × WuXi Biologics, and AbbVie × EvolveImmune, underscore the growing confidence in immune‑redirecting platforms and the sector’s commitment to accelerating innovation across oncology and autoimmune disease.
Now moving from Boston to San Diego for 2026, the 8th T‑Cell Engager Therapeutics Summit remains the industry’s most comprehensive end‑to‑end meeting dedicated exclusively to advancing, optimizing, and translating TCEs. This case‑study‑driven forum equips engineering, discovery, R&D, translational, and clinical development teams with the actionable insights needed to design safer, more potent, durable, and precisely targeted TCEs for solid tumors. The agenda also shines a spotlight on new applications expanding engager biology into autoimmune and inflammatory indications.
If accelerating your TCE pipeline is a priority, this is the meeting you cannot afford to miss.
What’s New in 2026?
Two Brand‑New Parallel Tracks
Tailor your learning across two dedicated streams: Discovery & Engineering and Preclinical to Clinical Translation, enabling deep dives aligned to your role and pipeline stage.
Fresh Clinical Insights in Combination & Precision Immunotherapy
Hear directly from Amgen and Regeneron as they reveal new clinical evidence on chemo‑immunotherapy integration, co‑stimulation pairings, and combination‑ready TCE design for deeper, more durable responses in solid tumors.
Explore the Full Event Guide
120+ Industry Attendees
28+ Expert Speakers
8+ Hours of Networking
6 Deep‑Dive Workshops
1 Modality at the Center
The Only Forum Advancing TCEs Across Oncology & Autoimmune Disease
View the Full Program – See all sessions, speakers, and workshops: https://ter.li/fulua0

4th Obesity & Weight Loss Drug Development Summit
2026-07-14 - 2026-07-16 | Hotel Commonwealth, 500 Commonwealth Avenue, Boston, MA, 02215, United States
Welcome to the 4th Obesity & Weight Loss Drug Development Summit – the definitive industry-forum dedicated to redefining the standards of metabolic medicine by mastering precision treatment, preserving functional health, and navigating the high-stakes transition to next-generation oral and multi-agonist therapies.
The obesity therapeutics market has entered a radical transformation. Driven by the unprecedented success of first-generation incretins, the landscape has reached a critical juncture where “simple weight loss” is no longer enough to win. As we move through 2026, the industry is under intense pressure to move beyond BMI-centric endpoints and unlock new levels of quality, targeting the 40% of adults globally who require more than a one-size-fits-all approach. The race is now on to decouple adipose reduction from skeletal muscle atrophy and secure long-term adherence through needle-free, scalable solutions that promise to transform chronic disease management forever.
The 4th Obesity & Weight Loss Drug Development Summit stands as the essential global forum for experts dedicated to accelerating this vital progress. This year, we are diving deep into the game-changing potential of multi-targeted portfolios, novel biological pathways and new modalities for a precision medicine approach, alongside the “Oral-First” revolution.
Hear from the titans of the pharmaceutical industry, including Novo Nordisk, Eli Lilly, and Merck & Co., as well as innovative biotechs such as Veru Inc., Canary Cure, and Metsera, who will share their ground-breaking research on preserving lean mass and preventing post-treatment weight regain.
Don’t miss this pivotal opportunity to network with 120+ leading experts in the field of advanced obesity therapeutics. Forge crucial collaborations and be part of the solution that will define the 2026 pipeline.
View the full event guide: https://ter.li/p453jn

2nd Operationalize: Expanded Access Programs Summit West
2026-07-14 - 2026-07-16 | Hyatt Centric Fisherman’s Wharf, 555 North Point Street, San Francsico, CA, 94133, United States
Across the West Coast, Expanded Access Programs are entering a new phase. More companies are launching EAPs earlier in development, supporting patients for longer durations, and extending access beyond the U.S. into increasingly complex global markets. What was once a reactive, exception-based activity is now a visible, repeatable function – bringing heightened expectations around governance, post-trial access, sustainability, and real-world insight generation, all while ensuring patients are not delayed or disadvantaged.
The 2nd Operationalize: Expanded Access Programs Summit West arrives at a critical moment. Purpose-built for West Coast biotech and pharma teams, this summit brings together senior leaders across Access, Medical Affairs, Clinical Operations, Regulatory, and Clinical Supply to share how EAPs are being designed, governed, and scaled in today’s environment.
Over three focused days, the summit tackles the most pressing questions facing EAP teams in 2026 – from navigating evolving U.S. and global regulatory expectations, to enabling providers and patient advocates, designing post-trial access strategies, managing long-duration and rare disease programs, and applying real-world insights without slowing access.
This is not a theoretical discussion. It is a peer-led, non-competitive forum for teams responsible for delivering access at scale – and for those shaping what Expanded Access must become next.
To know more visit: https://ter.li/gk0u1gt1

6th mRNA-Based Therapeutics Summit
2026-07-20 - 2026-07-22 | The Westin Boston Seaport District, 425 Summer Street, Boston, MA, 02210, United States
The 6th mRNA‑Based Therapeutics Summit: Accelerating the Next Era of mRNA Medicines
The global mRNA landscape is advancing at unprecedented speed, propelled by scientific breakthroughs and high‑impact biopharma investment. Recent acquisitions – including Eli Lilly and Orna, BMS and Orbital, AbbVie and Capstan, and BioNTech and CureVac – underscore the momentum behind emerging modalities such as in vivo CAR‑T, gene editing, and cancer immunotherapies as they move closer to clinical validation and commercial potential.
Amid this rapid evolution, the 6th mRNA‑Based Therapeutics Summit returns to Boston this summer as the world’s most influential meeting dedicated to mRNA science and drug development. Bringing together 350+ global leaders from established pharma innovators to trailblazing start‑ups – including Moderna, Pfizer, AstraZeneca, Sanofi, ParcelBio, CaVos Therapeutics and Kernal Biologics – as well as regulators from the US FDA, MHRA and EMA, the summit serves as the central forum shaping the future of mRNA technology.
This year’s revitalized agenda spans three core tracks – Discovery, Pre‑Clinical & Clinical Development, and Manufacturing & CMC – while introducing two brand‑new focus days on AI‑Driven mRNA Design and Next‑Generation Delivery Technologies. Across scientific sessions, case studies, and collaborative discussions, attendees will gain exclusive access to emerging data, regulatory expectations, and the partnerships driving mRNA toward its next frontier.
With 1,988 mRNA assets currently moving through global pipelines, the field is scaling faster than ever. The 2026 summit is strategically timed to spotlight major advancements across linear, circular, and self‑amplifying RNA platforms; next‑generation vaccine innovation and expanding clinical progress in oncology, rare diseases, autoimmune conditions, and beyond.
As the flagship global gathering for mRNA innovators, this summit remains the definitive place to connect with key decision makers, forge new strategic partnerships, and refine development and delivery strategies. From protein replacement to cell and gene therapeutics and transformative delivery technologies, the 6th mRNA‑Based Therapeutics Summit equips teams with the insights, networks, and momentum needed to accelerate candidates to clinical and commercial success and ultimately deliver life‑changing medicines to patients worldwide.
To know more visit: https://ter.li/axdw1v

5th Liquid Biopsy for Precision Oncology Summit East Coast
2026-07-20 - 2026-07-22 | Westin Boston Seaport, 425 Summer Street, Boston, MA, 02210, United States
The 5th Liquid Biopsy for Precision Oncology Summit East Coast returns as your laser-focused forum dedicated to the acceleration, progression and real-world adoption of liquid biopsies. Expect to unite with 100+ biopharma professionals from Pfizer, AbbVie, Takeda, AstraZeneca, GSK and more to redefine your clinical trial strategies and advance oncology drug development forward.
Boasting a speaker faculty consisting of over 70% large pharma, alongside leading biotech and consortia, this year’s meeting will not just be a forum to listen. It will be where the practical conversations shaping future decisions on patient stratification, MRD implementation and dose optimization happen in real time.
Take a sneak peek at what lies ahead this year:

Identify why pharma must be the ones to lead early detection in a session led by the Global Senior Director, Early Detection at AstraZeneca
Utilize ctDNA dynamics as an early measure of treatment effect to go beyond RECIST in a presentation hosted by the Chief Executive Officer at Marengo Therapeutics
Hear how senior pharma leaders at AbbVie, Takeda, AstraZeneca and GSK are rewriting drug development decisions with novel liquid biopsies
Discover how you can accelerate clinical development with ctDNA clearance and multi-omic profiling in an exclusive discussion moderated by the Director, Next-Generation Diagnostics at Novartis

Whether you’re evaluating the right liquid biopsy platform for your specific trial, looking to gain peer-insight into ctDNA and multi-omic profiling, or aligning internal strategies with evolving regulatory expectations, this meeting will provide you with the clarity, and confidence to take that next step.
Together let’s harness the power of liquid biopsies to drive smarter, better and more precise clinical decisions for patients in need.
To learn more and register, please click here.

6th Medical Device Software Development Summit
2026-07-21 - 2026-07-23 | Hotel AKA Back Bay, 154 Berkeley St, Boston, MA, 02116, United States
The 6th Medical Device Software Development Summit returns this July in Boston and brings together the specialists who are defining how AI-driven and software-based medical devices are built, validated, and submitted in an increasingly complex regulatory environment.
AI is accelerating innovation faster than traditional compliance models can keep up. FDA expectations for AI-enabled devices continue to evolve, cybersecurity scrutiny is intensifying, and global regulations such as the EU AI Act are adding new layers of complexity. The summit provides the clarity needed to navigate this shift by focusing on the real-world application of AI, automation, model development, and lifecycle management in regulated device environments.
Across three days of technical sessions and workshops, you will learn how leading teams are integrating AI responsibly, reducing regulatory risk, and strengthening product development pipelines. Speakers will break down practical frameworks for safe and compliant AI integration, including model validation, data quality, transparency expectations, documentation strategies, and global submission planning. Sessions also explore how continuous deployment and code generation tools can be aligned with compliance requirements.
You will:

Gain clear insight into evolving FDA expectations for AI-enabled and learning devices
Learn best practices for AI model development, validation, and deployment across the product lifecycle
Explore cybersecurity architectures that protect AI-driven systems from emerging risks
Understand how companies are modernizing development workflows through automation and AI-assisted engineering while maintaining compliance
Benchmark with software, regulatory, quality, cybersecurity, and product leaders who openly share real-world implementations and lessons

With a focused senior-level audience, discussions are practical, detailed, and grounded in real use cases instead of high-level theory. If your team is building or validating AI-enabled medical device software in 2026, this summit is the most concentrated source of guidance on how to innovate safely, accelerate approvals, and future-proof your roadmap in a rapidly shifting landscape.
Join the community leading the next generation of AI-driven medical device software and gain the insight and tools needed to advance your program with confidence.
To learn more and register online, please click here.

9th International Neoantigen Summit
2026-07-21 - 2026-07-23 | Park Plaza Amsterdam Victoria, Damrak 1-5, 1012 LG, Amsterdam, Netherlands
As the only conference focused on neoantigens, the 9th International Neoantigen Summit returns to Amsterdam as the most timely and essential gathering for the field. As your only chance this year to learn about the latest clinical data in the field and address the full translational journey – from antigen identification and validation through to biomarker strategy, clinical trial readouts and therapeutic efficacy – it’s not one to miss.
With a sharp focus on optimising translational testing, strengthening neoantigen validation and advancing novel personalised and off‑the‑shelf approaches, the conference is designed to help the industry streamline clinical trials and develop durable therapies with high immune response.
Over 3 immersive days, the summit will unite 70+ C‑level executives, directors, heads and senior scientists from leading biopharma organisations across Europe and the US. Attendees span:

Cancer immunotherapy
Antigen discovery
Bioinformatics
AI‑driven validation
Preclinical and clinical development
Regulatory strategy

All brought together by a shared mission to unlock the full potential of neoantigen‑targeted therapies.
With 6 new speaking companies, including Black Canyon Bio, CellVax Therapeutics, Echo Immune, Epitopea, Khosen Bio and Treos Bio, the summit convenes industry pioneers including Nykode Therapeutics, Evaxion, Geneos, and other leading innovators shaping the next generation of immunotherapies. Every session is curated for relevance, and every interaction is designed to foster meaningful collaboration.
Participants can expect critical clinical data updates, practical insights into bioinformatics and AI applications, strategies for clinical trial design and execution, and guidance on translating preclinical findings into successful clinical outcomes. More than a conference, this is the only annual checkpoint for the neoantigen community – a one‑stop platform to benchmark progress, uncover breakthroughs and build the partnerships that will drive the next wave of neoantigen‑targeted therapies forward.

4th ADC Linker & Conjugation Summit
2026-07-28 - 2026-07-30 | Revere Hotel Boston Common, 200 Stuart Street, Boston, 02116, United States
4th ADC Linker & Conjugation Summit
Linking Chemistry to Clinical Success Through Better ADC Design

When? July 28-30, 2026
Where? Boston, MA

ADC development is evolving fast, with developers pushing beyond traditional cytotoxins into dual‑payload constructs, high‑DAR species, degrader–antibody conjugates, and next‑generation modalities. This surge in innovation is placing new pressure on linker architecture and conjugation chemistry to improve stability, reduce off‑target toxicity, and maintain manufacturability at scale.
The 4th ADC Linker & Conjugation Summit returns this July as the only meeting dedicated exclusively to overcoming these chemistry‑centric challenges. Built specifically for ADC chemists, protein engineers, and bioconjugation specialists, the summit offers a highly curated setting where every session speaks directly to the scientific bottlenecks shaping next‑generation ADC performance. Attendees join peers with the same technical focus, ensuring every conversation is relevant and grounded in real‑world ADC development needs.Across three focused days, more than 80 scientific experts will dissect the mechanisms driving linker stability, conjugation precision, and payload behavior. The program features 20+ industry‑led case studies covering homogeneous ADC design, controlling premature payload release, dual‑payload engineering, hydrophobicity‑driven aggregation, and the integration of predictive modeling into conjugation strategies. These sessions reflect broader industry priorities, where site‑specific conjugation, next‑generation linkers, and stability optimization remain top areas of innovation.
This year introduces expanded workshops and interactive debates, including new sessions examining how to more effectively connect linker chemistry to translational outcomes and how to redesign payloads using emerging linker technologies. The 2026 meeting also welcomes 17 new speakers from 13 new companies, offering fresh insight into the rapidly diversifying toolkit available for ADC design.
For scientists working at the core of ADC chemistry, this summit provides a rare opportunity to benchmark strategies, challenge assumptions, and contribute to the next decade of linker and conjugation innovation.
View the full program and explore the 2026 agenda
Download the event guide here: https://ter.li/7pj7r6

5th In Vivo Cell Engineering & Gene Editing Summit
2026-07-28 - 2026-07-30 | Hotel Commonwealth, 500 Commonwealth Avenue, Boston, MA, 02215, United States
The 5th In Vivo Cell Engineering & Gene Editing Summit returns as the leading industry meeting dedicated to advancing the next generation of in vivo delivery platforms, gene editing tools, and translational strategies that support safe, precise, and scalable genetic medicines. Designed for scientists, technical leaders, and strategic decision-makers across biopharma, this summit provides a focused forum to exchange practical insights that directly influence scientific and clinical progress.
This year’s faculty brings together experts from cutting-edge biotechnology companies and global pharmaceutical organizations, including leaders from AstraZeneca, Pfizer, Eli Lilly, Ensoma, Capstan Therapeutics, Verve Therapeutics, nChrioma Bio, and more. Their collective experience spans delivery system innovation, payload engineering, translational development, and early clinical execution, giving delegates a clear view of what is required to successfully advance in vivo platforms.
Over three days of data-driven discussion, attendees will explore the latest advancements in lipid nanoparticle engineering, viral and nonviral vector optimization, capsid evolution, and emerging delivery technologies for targeted, efficient editing. Sessions will detail how teams are engineering payloads to enhance potency, durability, safety, and manufacturability. Speakers will also share frameworks for designing rigorous preclinical packages that address biodistribution, immunogenicity, and off-target risk early in development.
The summit places a strong focus on translational and early clinical learnings, with case studies that reveal how organizations are approaching dose selection, biomarker development, patient monitoring, and regulatory positioning. These insights provide an unfiltered look at what has worked in real programs and how teams are adjusting strategies to improve clinical readiness.
Delegates will benefit from a mix of scientific depth and strategic clarity. Whether you are building new delivery platforms, advancing editing tools, refining analytical approaches, or preparing a therapy for first-in-human studies, this meeting helps you benchmark your progress and sharpen decision-making.
Join peers who are driving the future of in vivo gene editing and cell engineering. This summit delivers the connections, evidence-based insights, and collaborative environment needed to progress transformative genetic medicines.
To learn more and register online, please click here.
